Hidradenitis Suppurativa (HS) is a skin condition causing painful lumps. This study checks if a new drug, remibrutinib, works well and is safe for adults with moderate to severe HS. The study lasts about 76 weeks. For the first 16 weeks, participants get either remibrutinib or a placebo (a dummy pill). After that, everyone gets remibrutinib for 52 weeks. There's also a 4-week check-up at the end. People can join if they're 18 or older and have had HS for at least 6 months, affecting two body areas with at least 5 painful lumps. You can't join if you have certain health issues, have had more than 20 draining tunnels, or have taken similar drugs before. The study involves regular check-ups and tests to make sure you're safe and healthy.

• The study is 76 weeks long with regular visits.
• If you quit early, you can still stay for follow-up checks.
• Participants must be 18+, with moderate to severe HS.